Literature DB >> 27446399

Expression levels of JNK associated with polymorphic lactotransferrin haplotypes in human nasopharyngeal carcinoma.

Gengqiu Luo1, Yanhong Zhou2, Wei Yi2, Hong Yi3.   

Abstract

Lactotransferrin (LTF), a member of the transferrin family, serves a role in the innate immune response and is involved in anti-inflammatory, anti-microbial and anti-tumor activity. Alterations in the LTF gene are associated with an increased incidence of cancer. The LTF gene is polymorphic, and several common alleles may be observed in the general population. Our previous study identified a lower rate of occurrence of the 'A-G-G-T' haplotype (constructed with rs1126477, rs1126478, rs2073495 and rs9110) in nasopharyngeal carcinoma (NPC) patients compared with controls. In the present study, in order to elucidate a possible mechanism of LTF-mediated anti-tumor activity in NPC, the protein profiles of NPC and non-tumorous nasopharyngeal epithelium tissues with/without the 'A-G-G-T' haplotype were constructed using LTQ Orbitrap technology. The results revealed that c-Jun N-terminal kinase 2 (JNK2) was highly expressed in NPC tissues and non-tumor nasopharyngeal epithelium tissues without the 'A-G-G-T' haplotype. These results were confirmed by western blot analysis. Furthermore, microRNA (miRNA) microarray analysis was conducted to investigate the differential miRNA profiles of NPC and non-tumor nasopharyngeal epithelium tissues with/without the 'A-G-G-T' haplotype. It was observed that hsa-miR-1256 and hsa-miR-659, which are potentially targeted to the JNK2 gene, were downregulated in NPC tissues without the 'A-G-G-T' haplotype. Hsa-miR-298, another miRNA potentially targeted to the JNK2 gene, was downregulated in non-tumor nasopharyngeal epithelium tissues without the 'A-G-G-T' haplotype. In summary, these results suggested that the expression levels of JNK2 may be associated with polymorphic LTF haplotypes in human NPC.

Entities:  

Keywords:  JNK2; expression; lactotransferrin; nasopharyngeal carcinoma

Year:  2016        PMID: 27446399      PMCID: PMC4950711          DOI: 10.3892/ol.2016.4723

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  39 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  The relationship of haplotype in lactotransferrin and its expression levels in Chinese Han ovarian cancer.

Authors:  Lanqin Cao; Yanhong Zhou; Xin Li; Hong Yi
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2011-09-20       Impact factor: 3.848

3.  Epigenetic deregulation of miR-29a and miR-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion.

Authors:  Yiwei Li; Dejuan Kong; Aamir Ahmad; Bin Bao; Gregory Dyson; Fazlul H Sarkar
Journal:  Epigenetics       Date:  2012-07-18       Impact factor: 4.528

4.  Down-regulation of miRNA-204 by LMP-1 enhances CDC42 activity and facilitates invasion of EBV-associated nasopharyngeal carcinoma cells.

Authors:  Lei Ma; Xubin Deng; Minhua Wu; Gong Zhang; Jianqing Huang
Journal:  FEBS Lett       Date:  2014-03-05       Impact factor: 4.124

Review 5.  Lactoferrin for prevention of neonatal infections.

Authors:  Paolo Manzoni; Michael Mostert; Mauro Stronati
Journal:  Curr Opin Infect Dis       Date:  2011-06       Impact factor: 4.915

6.  Functional characterization of the MECP2/IRAK1 lupus risk haplotype in human T cells and a human MECP2 transgenic mouse.

Authors:  Kristi A Koelsch; Ryan Webb; Matlock Jeffries; Mikhail G Dozmorov; Mark Barton Frank; Joel M Guthridge; Judith A James; Jonathan D Wren; Amr H Sawalha
Journal:  J Autoimmun       Date:  2013-02-18       Impact factor: 7.094

7.  Lactotransferrin: a candidate tumor suppressor-Deficient expression in human nasopharyngeal carcinoma and inhibition of NPC cell proliferation by modulating the mitogen-activated protein kinase pathway.

Authors:  Yanhong Zhou; Zhaoyang Zeng; Wenling Zhang; Wei Xiong; Minghua Wu; Yixin Tan; Wei Yi; Lan Xiao; Xiaoling Li; Chen Huang; Li Cao; Ke Tang; Xiayu Li; Shourong Shen; Guiyuan Li
Journal:  Int J Cancer       Date:  2008-11-01       Impact factor: 7.396

8.  One of two human lactoferrin variants exhibits increased antibacterial and transcriptional activation activities and is associated with localized juvenile periodontitis.

Authors:  Kabilan Velliyagounder; Jeffrey B Kaplan; David Furgang; Diana Legarda; Gill Diamond; Ruth E Parkin; Daniel H Fine
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

9.  Genetic variants may play an important role in mRNA-miRNA interaction: evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379.

Authors:  Anneke N Werk; Henrike Bruckmueller; Sierk Haenisch; Ingolf Cascorbi
Journal:  Pharmacogenet Genomics       Date:  2014-06       Impact factor: 2.089

Review 10.  MicroRNAs in nasopharyngeal carcinoma.

Authors:  Jeff P Bruce; Fei-Fei Liu
Journal:  Chin J Cancer       Date:  2014-11
View more
  3 in total

1.  circHECTD1 facilitates glutaminolysis to promote gastric cancer progression by targeting miR-1256 and activating β-catenin/c-Myc signaling.

Authors:  Juan Cai; Zhiqiang Chen; Jinguo Wang; Junfeng Wang; Xianjun Chen; Linhu Liang; Min Huang; Zhengrong Zhang; Xueliang Zuo
Journal:  Cell Death Dis       Date:  2019-08-02       Impact factor: 8.469

2.  Three-microRNA expression signature predicts survival in triple-negative breast cancer.

Authors:  Xinquan Wu; Mingji Ding; Jianqin Lin
Journal:  Oncol Lett       Date:  2019-11-19       Impact factor: 2.967

3.  MicroRNA-298 reduces levels of human amyloid-β precursor protein (APP), β-site APP-converting enzyme 1 (BACE1) and specific tau protein moieties.

Authors:  Nipun Chopra; Ruizhi Wang; Bryan Maloney; Kwangsik Nho; John S Beck; Naemeh Pourshafie; Alexander Niculescu; Andrew J Saykin; Carlo Rinaldi; Scott E Counts; Debomoy K Lahiri
Journal:  Mol Psychiatry       Date:  2020-01-15       Impact factor: 15.992

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.